We can’t show the full text here under this license.
Abstract
Essence
This article argues that repurposed mRNA vaccines, including COVID-19 vaccines, may help make checkpoint immunotherapy work better by reshaping the tumor immune environment.
Evidence
Mechanistic commentary/review drawing on prior study findings that mRNA-lipid nanoparticle vaccination can counter tumor immune evasion and support polyclonal antitumor CD8 T-cell responses.
Caveat
Because this is a perspective built on prior mechanistic and translational evidence rather than a new clinical trial, it does not directly prove efficacy in patients.
Simplified
mRNA Technology